Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 20 articles:
HTML format



Single Articles


    April 2021
  1. KHAN MT, Irlam-Jones JJ, Pereira RR, Lane B, et al
    A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01326.
    PubMed     Abstract available


    September 2020
  2. VOSS MH, Gordon MS, Mita M, Rini B, et al
    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Br J Cancer. 2020 Sep 11. pii: 10.1038/s41416-020-01041.
    PubMed     Abstract available


    August 2020
  3. REZENDE LFM, Lee DH, Keum N, Wu K, et al
    Resistance training and total and site-specific cancer risk: a prospective cohort study of 33,787 US men.
    Br J Cancer. 2020;123:666-672.
    PubMed     Abstract available


    July 2020
  4. PATTARAWAT P, Hong T, Wallace S, Hu Y, et al
    Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
    Br J Cancer. 2020;123:226-239.
    PubMed     Abstract available


    December 2019
  5. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    PubMed     Abstract available


    November 2019
  6. KITA Y, Hamada A, Saito R, Teramoto Y, et al
    Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies.
    Br J Cancer. 2019 Nov 1. pii: 10.1038/s41416-019-0609.
    PubMed     Abstract available


    March 2019
  7. IHIRA H, Sawada N, Yamaji T, Goto A, et al
    Physical activity and subsequent risk of kidney, bladder and upper urinary tract cancer in the Japanese population: the Japan Public Health Centre-based Prospective Study.
    Br J Cancer. 2019;120:571-574.
    PubMed     Abstract available


    February 2019
  8. DUFOUR F, Silina L, Neyret-Kahn H, Moreno-Vega A, et al
    TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
    Br J Cancer. 2019 Feb 15. pii: 10.1038/s41416-019-0397.
    PubMed     Abstract available


    October 2018
  9. AVGERIS M, Tsilimantou A, Levis PK, Tokas T, et al
    Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients.
    Br J Cancer. 2018 Oct 30. pii: 10.1038/s41416-018-0320.
    PubMed     Abstract available


  10. OOKI A, VandenBussche CJ, Kates M, Hahn NM, et al
    CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0291.
    PubMed     Abstract available


    July 2018
  11. SMITTENAAR P, Walker AK, McGill S, Kartsonaki C, et al
    Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer.
    Br J Cancer. 2018 Jul 11. pii: 10.1038/s41416-018-0156.
    PubMed     Abstract available


    May 2018
  12. MASON SJ, Downing A, Wright P, Hounsome L, et al
    Health-related quality of life after treatment for bladder cancer in England.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0084.
    PubMed     Abstract available


    February 2018
  13. SAKAGUCHI T, Yoshino H, Yonemori M, Miyamoto K, et al
    Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer.
    Br J Cancer. 2018 Feb 13. pii: bjc2017439. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    November 2017
  14. KASHIWAGI E, Inoue S, Mizushima T, Chen J, et al
    Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    October 2017
  15. MORERA DS, Hennig MS, Talukder A, Lokeshwar SD, et al
    Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    September 2017
  16. KOSHIARIS C, Aveyard P, Oke J, Ryan R, et al
    Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    July 2017
  17. DESCOTES F, Kara N, Decaussin-Petrucci M, Piaton E, et al
    Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    March 2017
  18. SAKAGUCHI T, Yoshino H, Yonemori M, Miyamoto K, et al
    Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    January 2017
  19. CHOUDHURY A, West CM, Porta N, Hall E, et al
    The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
    Br J Cancer. 2017 Jan 26. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    December 2016
  20. PARDINI B, Viberti C, Naccarati A, Allione A, et al
    Increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of bladder cancer.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: